816 related articles for article (PubMed ID: 28554322)
1. Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment.
Deng S; Lin Z; Li W
Curr Med Chem; 2017; 24(23):2505-2527. PubMed ID: 28554322
[TBL] [Abstract][Full Text] [Related]
2. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
3. Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer.
Najminejad Z; Dehghani F; Mirzaei Y; Mer AH; Saghi SA; Abdolvahab MH; Bagheri N; Meyfour A; Jafari A; Jahandideh S; Gharibi T; Amirkhani Z; Delam H; Mashatan N; Shahsavarani H; Abdollahpour-Alitappeh M
Mol Ther; 2023 Jul; 31(7):1874-1903. PubMed ID: 36950736
[TBL] [Abstract][Full Text] [Related]
4. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
[TBL] [Abstract][Full Text] [Related]
5. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.
von Arx C; De Placido P; Caltavituro A; Di Rienzo R; Buonaiuto R; De Laurentiis M; Arpino G; Puglisi F; Giuliano M; Del Mastro L
Cancer Treat Rev; 2023 Feb; 113():102500. PubMed ID: 36587473
[TBL] [Abstract][Full Text] [Related]
6. Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer.
Najjar MK; Manore SG; Regua AT; Lo HW
Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360302
[TBL] [Abstract][Full Text] [Related]
7. Antibody-Drug Conjugates for Breast Cancer Treatment: Emerging Agents, Targets and Future Directions.
Yang T; Li W; Huang T; Zhou J
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569276
[TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates in breast cancer: the chemotherapy of the future?
Nicolò E; Zagami P; Curigliano G
Curr Opin Oncol; 2020 Sep; 32(5):494-502. PubMed ID: 32657795
[TBL] [Abstract][Full Text] [Related]
9. Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2.
Abelman RO; Medford A; Spring L; Bardia A
Cancer J; 2022 Nov-Dec 01; 28(6):423-428. PubMed ID: 36383904
[TBL] [Abstract][Full Text] [Related]
10. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
Baron JM; Boster BL; Barnett CM
J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
[TBL] [Abstract][Full Text] [Related]
11. Antibody-targeted drugs and drug resistance--challenges and solutions.
Shefet-Carasso L; Benhar I
Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
[TBL] [Abstract][Full Text] [Related]
12. Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.
Pondé N; Aftimos P; Piccart M
Curr Treat Options Oncol; 2019 Apr; 20(5):37. PubMed ID: 30931493
[TBL] [Abstract][Full Text] [Related]
13. Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions.
Yu J; Li M; Liu X; Wu S; Li R; Jiang Y; Zheng J; Li Z; Xin K; Xu Z; Li S; Chen X
Biomed Pharmacother; 2024 May; 174():116522. PubMed ID: 38565055
[TBL] [Abstract][Full Text] [Related]
14. Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.
Jerjian TV; Glode AE; Thompson LA; O'Bryant CL
Pharmacotherapy; 2016 Jan; 36(1):99-116. PubMed ID: 26799352
[TBL] [Abstract][Full Text] [Related]
15. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
Yamada K; Ito Y
Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
[TBL] [Abstract][Full Text] [Related]
16. Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer.
Rassy E; Rached L; Pistilli B
Breast; 2022 Dec; 66():217-226. PubMed ID: 36334569
[TBL] [Abstract][Full Text] [Related]
17. Antibody-Drug Conjugates for Cancer Therapy.
Hafeez U; Parakh S; Gan HK; Scott AM
Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
[TBL] [Abstract][Full Text] [Related]
18. Developments in the use of antibody-drug conjugates.
Burris HA
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714468
[TBL] [Abstract][Full Text] [Related]
19. Antibody-Drug Conjugates: The New Frontier of Chemotherapy.
Ponziani S; Di Vittorio G; Pitari G; Cimini AM; Ardini M; Gentile R; Iacobelli S; Sala G; Capone E; Flavell DJ; Ippoliti R; Giansanti F
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752132
[TBL] [Abstract][Full Text] [Related]
20. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
